熱景生物(688068.SH)前三季度淨利潤降29.11%至1322.71萬元
格隆匯10月29日丨熱景生物(688068.SH)發佈2019年前三季度報告,實現營業收入1.38億元,同比增長13.20%;歸屬於上市公司股東的淨利潤1322.71萬元,同比下降29.11%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1109.93萬元,同比下降34.60%;基本每股收益0.28元。
毛利率由上年同期的74.27%下降到本期的72.54%,下降1.73個百分點;毛利率下降的主要原因是檢測儀器的毛利率由去年同期的61.47%下降到本期的29.15%,具體原因為公共安全領域儀器銷售比上年同期減少575.75萬元(對應毛利減少369.67萬元),造成綜合毛利率的下降。
歸屬於上市公司股東的淨利潤:下降543.27萬元,降幅29.11%,主要原因是(1)公司試劑銷售的季節性因素影響,2016年至2018年公司收入和淨利潤分佈具有一定季節性,其中第四季度的收入和淨利潤貢獻分別為29.81%、32.40%、34.92%以及21.60%、55.93%、61.66%;(2)公共安全領域儀器銷售比上年同期減少575.75萬元(對應毛利減少369.67萬元);(3)銷售費用、研發費用、管理費用等期間費用增加較多,對利潤也有一定影響。公司臨牀領域銷售仍然保持較快增長,其中肝臟疾病類試劑銷售比上年同期增長550.25萬元,增幅29.63%;磁微粒化學發光試劑收入相比去年同期增加2173.73萬元,增幅119.61%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.